Brief: Synairgen Plc Announces Topline Results From Phase 3 Sprinter Trial

Synairgen

21/02/2022 08:53

Feb 21 (Reuters) - Synairgen PLC  SYNG.L :
    * SYNAIRGEN PLC  - TOPLINE RESULTS FROM PHASE 3 SPRINTER
TRIAL
    * SYNAIRGEN : INTERNATIONAL PHASE 3 SPRINTER TRIAL IN
PATIENTS
HOSPITALISED WITH COVID-19 DID NOT MEET ITS PRIMARY OR KEY
SECONDARY EFFICACY ENDPOINTS
    * SYNAIRGEN PLC: SNG001 DEMONSTRATED A FAVOURABLE SAFETY
PROFILE
AND WAS WELL TOLERATED IN THIS POPULATION.
    * SYNAIRGEN PLC: IMPROVEMENT IN PATIENT CARE MAY HAVE
COMPROMISED
POTENTIAL OF SNG001 TO SHOW A CLINICAL BENEFIT IN RESPECT OF
ENDPOINTS
    * SYNAIRGEN PLC: WE AWAIT PHASE 2 DATA FROM US NIH ACTIV-2
TRIAL
IN HOME- BASED COVID-19 PATIENTS

Source text for Eikon:  ID:nRSU2097Ca 
Further company coverage:  SYNG.L 

 ((Reuters.Briefs@thomsonreuters.com;))